Novartis combo therapy for melanoma gets FDA priority review

ZURICH (Reuters) - The U.S. Food and Drug Administration has granted priority review for Novartis's Tafinlar in combination with Mekinist for treating some patients with advanced melanoma, the Swiss drugmaker said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news